Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "G-V-Prasad"

8 News Found

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI
News | December 17, 2023

Dr. Reddy's becomes first Indian pharma company to debut on the DJSI

Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis


Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
News | October 30, 2023

Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr

Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter


Adopt digitisation & automation for business sustainability and quality excellence : CEOs
News | March 01, 2022

Adopt digitisation & automation for business sustainability and quality excellence : CEOs

Pankaj Patel, Chairman, Zydus Lifesciences; Umang Vohra, CEO, Cipla; G V Prasad, Co-Chairman, Dr Reddy's; Nilesh Gupta, MD, Lupin and Dilip Shanghvi, MD, Sun Pharmaceuticals sharing their vision to outline the roadmap for the industry.


Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.
News | January 28, 2022

Dr Reddy’s Q3FY22 PAT at Rs. 706 cr.

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended December 31, 2021


Dr Reddys Laboratories  posts Q2FY22 PAT at Rs 992 Cr
News | November 01, 2021

Dr Reddys Laboratories posts Q2FY22 PAT at Rs 992 Cr

Dr. Reddy's Laboratories has reported consolidated financial results for the period ended September 30, 2021


Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr
News | July 28, 2021

Dr. Reddy's Laboratories Ltd Q1FY22 consolidated PAT at Rs. 380.4 Cr

The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.


Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT
News | May 15, 2021

Dr. Reddy's Laboratories see marginal dip in FY 2021 PAT

Dr. Reddy's Laboratories has reported total income of Rs.19338.9 crores during FY ended March 31, 2021


Dr. Reddy's initiates process for emergency use authorization of Sputnik V
News | February 20, 2021

Dr. Reddy's initiates process for emergency use authorization of Sputnik V

Dr. Reddy's will present the safety profile of the phase 2 study, and interim data of the phase 3 study, which is expected to complete by 2pt February 2021.